Follow-up investment in Hemotune

OCCIDENT has again taken the lead in the latest financing round of hemotune. With the fantastic support of existing and new investors, we are very pleased to contribute to such a relevant therapeutic area as sepsis with a technology that can benefit many patients in the future.

The team at hemotune has done a tremendous job over the last years and convinced us once again. With this funding, the company will be able to continue the very encouraging development of its platform device.

More information in the press release under the following Link.

More about hemotune

Follow-up investment in Tubulis Overview Resistell starts research project with Pfizer
Want to learn more about OCCIDENT?